Cargando…
HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature
Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). HRAS mutations involved around 0.2–0.8% of NSCLC patients, mostly on codon 61. For these patients, few data are available regarding cli...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139372/ https://www.ncbi.nlm.nih.gov/pubmed/35621690 http://dx.doi.org/10.3390/curroncol29050300 |
_version_ | 1784714844229861376 |
---|---|
author | Mathiot, Laurent Herbreteau, Guillaume Robin, Siméon Fenat, Charlotte Bennouna, Jaafar Blanquart, Christophe Denis, Marc Pons-Tostivint, Elvire |
author_facet | Mathiot, Laurent Herbreteau, Guillaume Robin, Siméon Fenat, Charlotte Bennouna, Jaafar Blanquart, Christophe Denis, Marc Pons-Tostivint, Elvire |
author_sort | Mathiot, Laurent |
collection | PubMed |
description | Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). HRAS mutations involved around 0.2–0.8% of NSCLC patients, mostly on codon 61. For these patients, few data are available regarding clinical characteristics and response to therapies. Methods: Next-Generation Sequencing (NGS) done routinely at Nantes University Hospital was used to identify HRAS molecular alterations in NSCLC patients. We identified and described four HRAS p.GlnQ61Leu mutated patients. Literature of previously HRAS-mutant NSCLC cases was reviewed, and available data in solid tumour with the most advanced H-Ras specific inhibitor, tipifarnib, were presented. Results: Of 1614 patients diagnosed with advanced NSCLC from January 2018 to December 2020, four (0.25%) had HRAS p.Gln61Leu mutation. Three of them died during the first-line systemic therapy. Furthermore, three additional cases were identified in literature. All cases were current or former smokers, most of them had pleural or pericardial effusion at diagnosis. Conclusions: The clinical course of patients with HRAS-mutant NSCLC remains unclear. Furthers cases should be identified in order to clarify prognosis and response to therapies. Tipifarnib, a farnesyl transferase inhibitor, is a promising candidate to target HRAS-mutant tumours and should be explored in NSCLC patients. |
format | Online Article Text |
id | pubmed-9139372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91393722022-05-28 HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature Mathiot, Laurent Herbreteau, Guillaume Robin, Siméon Fenat, Charlotte Bennouna, Jaafar Blanquart, Christophe Denis, Marc Pons-Tostivint, Elvire Curr Oncol Case Report Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). HRAS mutations involved around 0.2–0.8% of NSCLC patients, mostly on codon 61. For these patients, few data are available regarding clinical characteristics and response to therapies. Methods: Next-Generation Sequencing (NGS) done routinely at Nantes University Hospital was used to identify HRAS molecular alterations in NSCLC patients. We identified and described four HRAS p.GlnQ61Leu mutated patients. Literature of previously HRAS-mutant NSCLC cases was reviewed, and available data in solid tumour with the most advanced H-Ras specific inhibitor, tipifarnib, were presented. Results: Of 1614 patients diagnosed with advanced NSCLC from January 2018 to December 2020, four (0.25%) had HRAS p.Gln61Leu mutation. Three of them died during the first-line systemic therapy. Furthermore, three additional cases were identified in literature. All cases were current or former smokers, most of them had pleural or pericardial effusion at diagnosis. Conclusions: The clinical course of patients with HRAS-mutant NSCLC remains unclear. Furthers cases should be identified in order to clarify prognosis and response to therapies. Tipifarnib, a farnesyl transferase inhibitor, is a promising candidate to target HRAS-mutant tumours and should be explored in NSCLC patients. MDPI 2022-05-20 /pmc/articles/PMC9139372/ /pubmed/35621690 http://dx.doi.org/10.3390/curroncol29050300 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Mathiot, Laurent Herbreteau, Guillaume Robin, Siméon Fenat, Charlotte Bennouna, Jaafar Blanquart, Christophe Denis, Marc Pons-Tostivint, Elvire HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature |
title | HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature |
title_full | HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature |
title_fullStr | HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature |
title_full_unstemmed | HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature |
title_short | HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature |
title_sort | hras q61l mutation as a possible target for non-small cell lung cancer: case series and review of literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139372/ https://www.ncbi.nlm.nih.gov/pubmed/35621690 http://dx.doi.org/10.3390/curroncol29050300 |
work_keys_str_mv | AT mathiotlaurent hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature AT herbreteauguillaume hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature AT robinsimeon hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature AT fenatcharlotte hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature AT bennounajaafar hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature AT blanquartchristophe hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature AT denismarc hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature AT ponstostivintelvire hrasq61lmutationasapossibletargetfornonsmallcelllungcancercaseseriesandreviewofliterature |